Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain

Neurological Research

Volumn 35, Issue 9, 2013, Pages 948-958

  Sałat, Kinga ^a   Librowski, Tadeusz ^a   Nawiesniak, Barbara ^a   Gluch Lutwin, Monika ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

2, 2 Diphenyl 1 picrylhydrazyl radical; Glucose utilization; Lipid accumulation; Painful diabetic neuropathy; Pregabalin

Indexed keywords

1, 1 DIPHENYL 2 PICRYLHYDRAZYL; PREGABALIN; ROSIGLITAZONE; TERFENADINE; UNCLASSIFIED DRUG;

ADULT; ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DIABETIC NEUROPATHY; DRUG DOSE COMPARISON; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; HYPERALGESIA; LATENT PERIOD; LIPID STORAGE; MALE; METABOLISM; MOTOR COORDINATION; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; ROTAROD TEST; SPECTROPHOTOMETRY;

3T3-L1 CELLS; ANALGESICS; ANIMALS; ANTIOXIDANTS; CELL DEATH; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; GAMMA-AMINOBUTYRIC ACID; GLUCOSE; HEP G2 CELLS; HUMANS; HYPERALGESIA; LIPID METABOLISM; MALE; MICE; MOTOR SKILLS; NEURALGIA; PAIN THRESHOLD; TERFENADINE; THIAZOLIDINEDIONES;

EID: 84885662002     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132813Y.0000000236     Document Type: Article

References (68)

1. Baron R, Brunnmüller U, Brasser M, May M, Binder A. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain. 2008;12:850-58.
2. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-81.
3. Jääskeläinen SK. Pregabalin for painful neuropathy. Lancet Neurol. 2005;4:207-8.
4. Vinik A. CLINICAL REVIEW: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. 2005;90:4936-45.
5. Xochilcal-Morales M, Castro EM, Guajardo-Rosas J, Obregón TN, Acevedo JC, Chucan JM, et al. A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. Int J Clin Pract. 2010;64(9):1301-9.
6. Moon DE, Lee DI, Lee SC, Song SO, Yoon DM, Yoon MH, et al. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010;32: 2370-85.
7. Baron R, Freynhagen R, Tölle TR, Cloutier C, Leon T, Murphy TK, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150:420-7.
8. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs. 2007;67:569-85.
9. Davis MP. What is new in neuropathic pain? Support Care Cancer. 2007;15:363-72.
10. Takeuchi Y, Takasu K, Ono H, Tanabe M. Pregabalin, S-(z)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology. 2007;53(7):842-53.
11. Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem. 2009;9:71-8.
12. Pluijms W, Huygen F, Cheng J, Mekhail N, van Kleef M, Van Zundert J, et al. Evidence-based interventional pain medicine according to clinical diagnoses. 18. Painful diabetic polyneuropathy. Pain Pract. 2011;11:191-8.
13. Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR et al. Evidence-based guideline: treatment of painful diabetic neuropathy-report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve. 2011;43: 910-7.
14. Bril V. Treatments for diabetic neuropathy. J Peripher Nerv Syst. 2012;17(Suppl 2):22-7.
15. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebocontrolled trial. Diabet Med. 2011;28:109-16.
16. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev. 2008;24(Suppl 1):S52-7.
17. Zilliox L, Russell JW. Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol. 2011;13:143-59.
18. Rizzato B, Leone G, Misaggi G, Zivi I, Diomedi M. Efficacy and tolerability of pregabalin versus topiramate in the prophylaxis of chronic daily headache with analgesic overuse: an open-label prospective study. Clin Neuropharmacol. 2011;34:74-8.
19. Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr Dis Treat. 2008;4:1193-201.
20. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm. 2007;64:1475-82.
21. Tomson T, Almas M, Giordano S, Cabrera J. The impact of background antiepileptic drugs on the efficacy and safety of pregabalin in treating partial-onset seizures: a post hoc analysis of combined clinical trials. Epilepsy Res. 2011;96:64-73.
22. Attal N, Cruccu G, Baron R, HaanpääM, Hansson P, Jensen TS, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88.
23. Baidya DK, Agarwal A, Khanna P, Arora MK. Pregabalin in acute and chronic pain. J Anaesthesiol Clin Pharmacol. 2011;27:307-14.
24. Kim JS, Bashford G, Murphy TK, Martin A, Dror V, Cheung R. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain. 2011;152:1018-23.
25. Mittal M, Pasnoor M, Mummaneni RB, Khan S, McVey A, Saperstein D, et al. Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. Int J Neurosci. 2011;121:521-7.
26. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs. 2012;21:1019-29.
27. Park JM, Jwa SW, Song M, Kim HS, Ko HC, Kim MB, et al. Efficacy and safety of pregabalin for the treatment of chronic pruritus in Korea. J Dermatol. 2012;39:790-1.
28. Solak Y, Biyik Z, Atalay H, Gaipov A, Guney F, Turk S, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance hemodialysis patients: a prospective crossover study. Nephrology (Carlton) 2012;17(8):710-7.
29. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137-50.
30. Vorobeychik Y, Gordin V, Mao J, Chen L. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs. 2011;25:1023-34.
31. Vondracek P, Oslejskova H, Kepak T, Mazanek P, Sterba J, Rysava M, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009;13:332-6.
32. Rahman W, Bauer CS, Bannister K, Vonsy JL, Dolphin AC, Dickenson AH. Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Mol Pain. 2009;5:45.
33. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebocontrolled trial. Neurology. 2003;60:1274-83.
34. Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother. 2006;6:1629-35.
35. Tentolouris NK. Painful diabetic neuropathy-new choice of first-line therapy? Nat Rev Endocrinol. 2011;7:381-3.
36. Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203-13.
37. Luszczki JJ, Florek-Luszczki M. Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis. Pharmacol Rep. 2012;64(3):723-32.
38. Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology. 2002;97(5):1263-73.
39. Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67:1265-89.
40. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448-54.
41. Anastassiou E, Iatrou CA, Vlaikidis N, Vafiadou M, Stamatiou G, Plesia E, et al. ATLAS investigators. Impact of pregabalin treatment on pain, pain-elated sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig. 2011;31:417-26.
42. Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
43. Arnold LM, Emir B, Murphy TK, Zeiher BG, Pauer L, Scott G, et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther. 2012;34:1092-102.
44. Criswell KA, Cook JC, Morse D, LawtonM, Somps C, Obert L, et al. Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementation. Toxicol Sci. 2012;128:42-56.
45. Forde G. Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles. J Fam Pract. 2007;56:3-12.
46. Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs. 2004;64:2813-20.
47. Guay DR. Pregabalin in neuropathic pain: a more 'pharmaceutically elegant' gabapentin? Am J Geriatr Pharmacother. 2005;3:274-87.
48. Masa-Vázquez LA, Villamil-Cajoto I, Villar Del Castillo A. Efficacy and safety of pregabalin in neuropathic pain treatment: a still unreported adverse effect. Minerva Med. 2008;99:533-4.
49. Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf. 2012;11(3):487-502.
50. Tanabe M, Murakami T, Ono H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy. J Pharmacol Sci. 2008; 107(2):213-20.
51. Eddy N, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Ther. 1953;107: 385-93.
52. Talarek S, Orzelska J, Listos J, Fidecka S. Effects of sildenafil treatment on the development of tolerance to diazepaminduced motor impairment and sedation in mice. Pharmacol Rep. 2010;62(4):627-34.
53. Schlesier K, Harwat M, Böhm V, Bitsch R. Assessment of antioxidant activity by using different in vitro methods. Free Rad Res. 2002;36(2):177-87.
54. Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. Pain Pract. 2012;12:209-18.
55. Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract. 2011;11:167-79.
56. Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010;82:151-8.
57. Naylor HK, Raymond CB. Treatment of neuropathic pain in patients with chronic kidney disease. CANNT J. 2011;21:34-8.
58. Tanenberg RJ, Irving GA, Risser RC, Ahl J, Robinson MJ, Skljarevski V, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011;86:615-26.
59. Martinez JA, Kasamatsu M, Rosales-Hernandez A, Hanson LR, Frey WH, Toth CC. Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states. Mol Pain. 2012;8:3.
60. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-38.
61. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8-14.
62. Kuritzky L. Managing diabetic peripheral neuropathic pain in primary care. J Fam Pract. 2010;59:S15-22.
63. Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008;10:99-108.
64. Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med. 2007;8(Suppl 2):S43-49.
65. Pal P, Kanaujiya JK, Lochab S, Tripathi SB, Sanyal S, Behre G, et al. Proteomic analysis of rosiglitazone and guggulsterone treated 3T3-L1 preadipocytes. Mol Cell Biochem. 2013;376(1-2):81-93.
66. Li YY, Wu HS, Tang L, Feng CR, Yu JH, Li Y, et al. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo. Pharmacol Res. 2007;56(4):335-43.
67. Takazawa T, Yamauchi T, Tsuchida A, Takata M, Hada Y, Iwabu M, et al. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J Biol Chem. 2009;284(44):30049-57.
68. Janaszewska A, Bartosz G. Assay of total antioxidant capacity: comparison of four methods as applied to human blood plasma. Scand J Clin Lab Invest. 2002;62:231-6.